Breath-powered™ nasal delivery of powdered sumatriptan (AVP-825): Migraine disability and functional outcome in a phase 3 study (TARGET)

Authors
Category Primary study
ConferenceHeadache
Year 2014
This article has no abstract
Epistemonikos ID: 262304d84c7034f236c9f41e4ca26eb1a862f918
First added on: Apr 30, 2026